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Abstract 
Glucocorticoids, although being one of the eldest drugs in the clinic and despite their widespread usage for the 
treatment of inflammatory and immune disorders and cancer, have not yet come of age when it comes to a full 
understanding of how they work. The majority of the biological actions of glucocorticoid hormones are 
explained by a wide diversity in the cellular action mechanism of the hormone-activated Glucocorticoid 
Receptor (GR). All molecular mechanisms described in the current overview are not only complex, exhibiting an 
astonishing degree of gene- and tissue-specificity, but on top of this they are also non-exclusive. This layering of 
mechanisms makes it extremely difficult for researchers to extract the crucial pieces of information that would 
assist in a rational design of drugs with an improved therapeutic profile, i.e. a satisfying and maintained 
therapeutic response in the absence of the many incapacitating glucocorticoid-associated side effects, such as 
diabetes, osteoporosis, muscle wasting, depression etc. In direct correlation with increased glucocorticoid usage 
as observed in the clinic, the impetus and desire to reveal all of these mechanisms -and most importantly, to try 
to integrate them in a sensible manner for the sake of finding better alternatives- has never been stronger. 
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INTRODUCTION: THE CLINICAL 
IMPORTANCE OF  
GLUCOCORTICOIDS 
 
 In the late 1940s, a rheumatoid 
arthritis patient miraculously recovered 
from his symptoms, albeit temporarily, 
after treatment with cortisone. Following 
this observation, Hench, together with 
Kendall and Reichstein, received the Nobel 
Prize for their findings on the adrenal 
glucocorticoid hormone in 1950 (1). This 
hormone is derived from cholesterol, has a 
typical steroidal structure (Figure 1) and is 
secreted by the zona fasciculata of the 
adrenal gland. Glucocorticoids (GCs) play 
a pivotal role in various biological 
processes, such as metabolism, 
reproduction, development, inflammatory 
reactions and stress responses. GCs are 
regulated in a circadian and stress-
associated manner with the goal to 
maintain various metabolic and 
homeostatic functions that are necessary 
for life. The synthesis and release of 
natural glucocorticoids is subject to a 
circadian and ultradian rhythm, controlled 
by the hypothalamus-pituitary-adrenal axis
 
Figure 1. Steroidal structures. A. Chemical structure of cholesterol. B. Basic steroidal structure in which ‘R’ 
represents any side chain. C. Chemical structure of cortisone 
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(HPA-axis, Figure 2) (2,3), with the lowest 
levels reached late night-early morning. 
Hence, sufferers from asthma typically 
experience their fiercest attacks around that 
time (4). 
 Following the discovery of the 
therapeutic potential of cortisone, a wide 
range of synthetic derivatives have since 
revolutionized clinical medicine. Despite 
the wide range of side effects caused by 
pharmacological dosages of GCs, therapies 
based on these GCs are currently still the 
most effective treatment for all kinds of 
inflammatory and immune disorders. 
Examples are asthma, rheumatoid arthritis, 
inflammatory bowel disease, autoimmune 
diseases and transplant rejection. With 
regard to inflammation, it is well accepted 
that the therapeutic action of GCs is mainly 
achieved by the dampening of pro-
inflammatory signal transduction pathways 
and in consequence, the effective 
inhibition of multiple activated pro-
inflammatory genes. Additionally, due to 
their role in the induction of apoptosis 
(programmed cell death) and because of 
their anti-angiogenic and anti-emetic 
actions, GCs can be applied as a 
component of chemotherapy for the 
treatment of a number of cancers (5–7). 
Although also used to treat solid tumors 
(8), GCs constitute an important
 
Figure 2. Hypothalamus - Pituitary - Adrenal (HPA)-axis. Regulation of glucocorticoid, i.e. cortisol, 
production and release.  
Abbreviations: CRH, corticotropin-releasing hormone; ACTH, adrenocorticotropic hormone; GR, glucocorticoid 
receptor 
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part of the treatment of lymphoid 
malignancies (7,9). As a consequence of 
their broad action, GCs also cause a 
plethora of side effects, such as 
osteoporosis, muscle atrophy, 
hypertension, growth suppression in 
children, and abnormalities in glucose and 
fat metabolism, which limit the use of GCs 
as a robust, long-term therapy (5,7). In 
addition, the therapeutic effects decrease 
during treatment due to the gradual onset 
of glucocorticoid resistance, further 
limiting their action spectrum. The 
conundrum of GC resistance also poses a 
considerable problem to the scientific 
community, because the underlying 
mechanisms of GC resistance seem 
divergent, with a cell-type specific and 
highly controversial component (6,10,11). 
 
THE COMPLEXITY OF A 
WIDESPREAD GLUCOCORTICOID 
RECEPTOR BINDING ONTO 
GENOMIC REGIONS 
 
 GCs act via the Glucocorticoid 
Receptor (GR), a ligand-dependent 
transcription factor that belongs to the 
thyroid/steroid nuclear receptor 
superfamily (3,12). Both genomic and non-
genomic mechanisms for the action of 
glucocorticoids have been described (2). 
Due to their lipophilic nature, GCs can 
diffuse freely through the cell membrane 
and bind to the cytoplasmic GR (Figure 3). 
Ligand binding elicits a conformational 
change in the receptor, followed by the 
dissociation of heat shock proteins and 
nuclear translocation. Heat shock proteins 
serve as chaperoning proteins, with Hsp90 
and Hsp70 as the most important ones, 
enabling a net residence of the unliganded, 
inactive receptor in the cytosol. Once the 
ligand-bound receptor is in the nucleus, the 
expression of GC-responsive genes can be 
influenced in a positive or negative 
manner. Positive control is primarily 
mediated by transactivation, a process in 
which the ligand-activated, homodimeric 
GR binds to glucocorticoid response 
elements (GRE) via its centrally located 
DNA-binding domain (see chapter 3) 
(13,14). GREs are inducible enhancer 
elements in the promoter region of GC-
responsive genes and typically consist of 
one or more GR binding sequence (GBS), 
with the consensus sequence 5′-
AGAACANNNTGTTCT-3’ (15), and 
eventual binding motifs for non-GR 
transcriptional regulatory factors (16–18). 
Of note, GR target genes have been 
identified for which the GBS deviates from 
the above consensus sequence, which 
contribute to the diversity in GR signaling 
(2,16). It is important to point out a recent 
change in GRE nomenclature and to 
clearly make the distinction between the 
above described GREs and so-called GR 
binding regions (GBRs) in the genome, 
detected using genome-wide chromatin 
immunoprecipitation approaches 
(ChIPseq) and retrieved in a context-
dependent manner (e.g. varying dependent 
on the cell type) (Figure 4) (16). 
Intriguingly, a recent study of the 
Yamamoto team (16) elegantly showed 
that GBSs can dictate structural changes at 
the DNA-binding interface that are 
subsequently translated into changes in the 
GR dimerization interface, a phenomenon
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Figure 3. Activation of GR and GR-regulated transcription 
Glucocorticoids (GCs), such as cortisol, can diffuse across the plasma membrane. In the cytoplasm these GCs 
bind into the ligand-binding pocket of the glucocorticoid receptor (GR). Upon ligand binding, the GR dissociates 
from its cytoplasmic chaperoning molecules and travels to the nucleus where it can affect gene transcription via 
multiple mechanisms. The binding of homodimeric GR onto the GR-binding sequence (GBS) of a GC response 
element (GRE) results in enhanced transcription. Alternatively, inhibition of transcription is attained via binding 
of monomeric GR onto a negative GRE (nGRE) or binding of monomeric GR onto the transcription factors NF-
κB or AP-1. The latter tethering mechanisms are called transrepression. 
 
 
 
that is further transmitted into a distinct 
impact on the transcriptional outcome. 
Other regulating mechanisms for gene 
expression have also been described, such 
as binding of the GR to negative GREs, 
resulting in inhibition of gene expression 
(19). This mechanism however represents 
a minority within the whole of GR target 
genes. GR can also negatively interfere 
with the action of other activated 
transcription factors, such as the pro-
inflammatory Nuclear Factor-kappaB (NF-
κB) and Activator Protein-1 (AP-1). This 
mechanism, in which protein-protein 
interactions are involved, is referred to as 
transrepression (see chapter 7) (14). 
 A general assumption is that the 
unwanted effects are mainly caused by 
GR-mediated transactivation, while 
transrepression of various pro-
inflammatory genes accounts for the anti-
inflammatory potential of GCs. However, 
not all the side effects can be predictably 
prevented by an uncoupling of 
transactivation and transrepression. 
Exemplary herein is the Hypothalamic-
Pituitary-Adrenal (HPA) axis suppression, 
which relies on transrepression and would 
thus be sustained using transrepression- 
favouring GR ligands (20,21). And, vice 
versa, some important anti-inflammatory 
effects of GCs are caused by upregulating
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Figure 4. Graphical illustration of recent changes in GR-DNA interaction nomenclature 
While in the old nomenclature (A), the glucocorticoid response element (GRE) is preserved for the palindromic 
15bp sequence onto which homodimeric GR actually binds, the new nomenclature (B) has a wider understanding 
for a ‘GRE’ and lets it encompass the 15bp glucocorticoid receptor-binding sequence (GBS), as well as eventual 
adjacent regulatory elements. The glucocorticoid receptor-binding regions (GBRs) are DNA sequences, 
identified by genome-wide chromatin immunoprecipitation analyses, that show a positive signal for GR binding 
within the cleaved DNA strand. 
Abbreviations: GRE, glucocorticoid response element; GBS, glucocorticoid receptor-binding sequence; GBR, 
glucocorticoid receptor-binding region 
 
 
 
anti-inflammatory genes via 
transactivation, for instance the gene 
encoding the GC-Induced Leucine Zipper 
(GILZ) protein, DUSP1 (dual-specificity 
phosphatase 1), or the Inhibitor of NF-κB 
(IκBα) protein (20). 
 
THE COMPLEXITY OF 
GLUCOCORTICOID RECEPTOR 
ISOFORMS 
 
 GR is a modular protein composed 
of an N-terminal transactivation domain 
(NTD), a central DNA binding domain 
(DBD), a hinge region (HR) and a C-
terminal ligand binding domain (LBD) 
(Figure 5A). The NTD comprises a first 
transactivation domain, also called 
activation function 1 (AF1), which plays 
an important role in the recruitment of 
molecules necessary for the initiation of 
transcription. The DBD contains two zinc 
finger motifs that recognize and bind the 
GBSs. Furthermore, this domain contains 
sequences that are important for receptor 
dimerization, nuclear translocation and 
binding to other transcription factors. From 
an evolutionary perspective, the DBD is 
the most conserved domain among the 48 
members of the nuclear receptor 
superfamily. The LBD plays an essential 
role in the ligand-induced activation of the 
GR and contains a second transactivation 
domain, called AF2. This transactivation 
domain is, in contrast to AF1, ligand- 
dependent. The LBD also contains 
sequences involved in nuclear 
translocation, binding to heat shock 
proteins, receptor dimerization and 
interaction with coregulators. Coregulators 
are positive (coactivators) or negative 
(corepressors) regulatory proteins that are 
necessary for the transcriptional activity of 
the GR and are recruited by the receptor 
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Figure 5. Organization of the glucocorticoid receptor isoform hGRα-A 
A. Structural organization of the glucocorticoid receptor isoform hGRα-A. B. Post-translational modifications of 
hGRα-A (see chapter 4) 
Abbreviations: NTD, N-terminal domain; DBD, DNA-binding domain; HG, hinge region; LBD, ligand-binding 
domain; AF, activation function; P, phosphorylation; SUMO, sumoylation; Ub, ubiquitinylation; Ac, acetylation. 
 
 
 
through protein-protein interactions (22). 
Finally, there is a hinge region between the 
DBD and LBD, which gives structural 
flexibility to the GR. Because of this 
flexibility, a single receptor dimer can 
interact with multiple GREs (3,23). 
 Multiple isoforms of the human GR 
are generated by alternative RNA splicing 
and alternative translation initiation. The 
most common isoforms are GRα and GRβ, 
produced by alternative splicing of the last 
exon, exon 9, of the human NR3C1 gene. 
GRα is ubiquitously expressed and is the 
classic, ligand-dependent form of the 
receptor. GRβ, in contrast to GRα, does not 
bind to GCs and is transcriptionally 
inactive. Instead, it can have a dominant 
negative effect on the transcriptional 
activity of the GRα isoform and is 
therefore associated with GC resistance 
(2). Additional splice variants are detected 
in specific tissues and some have been 
associated with certain diseases, 
exemplified by the hGRγ isoform that has 
been detected in childhood acute 
lymphoblastic leukemia. Most of these 
variants are associated with a lower 
transcriptional activity. Besides these 
splice variants, there are numerous variants 
generated by alternative initiation, such as 
GRα-B, C1-3 and D1-3. These variants can 
display distinct expression, transactivation 
and transrepression patterns. As such, 
alternative splicing and translation 
initiation are additional mechanisms that 
regulate the expression of GC-target genes 
and can explain tissue- and disease-specific 
effects (2,3,24). 
P Belg Roy Acad Med Vol. 3:.33-52   S. J. Desmet et al. 
___________________________________________________________________________ 
40 
 
THE COMPLEXITY OF POST-
TRANSLATIONAL MODIFICATIONS 
 
 An additional regulatory level 
impacting the transcriptional activity of 
GR is achieved by post-translational 
modifications (PTM), including 
phosphorylation, acetylation, 
ubiquitinylation and SUMOylation (Figure 
5B). These modifications can influence 
numerous factors, such as subcellular 
localization, protein half-life, coregulator 
recruitment, ligand or DNA binding, and 
as a result the overall transcriptional 
activity of the receptor. The PTM of the 
receptor can be considered as a unique 
“code”, of which the composition depends 
on signals from both outside and inside the 
cell (25,26). 
 One of the best characterized 
modifications is phosphorylation. When 
phosphorylation occurs, a phosphate group 
is associated to a protein by a specific 
enzyme, namely a kinase. This association 
can be reversed via the action of other 
enzymes, called phosphatases. The GR has 
a low basal phosphorylation status and gets 
hyperphosphorylated following binding of 
an agonist. Phosphorylation of the serine 
residue at position 211 (S211) is 
considered as a hallmark for its 
transactivation potential (25,26). Ligand 
binding also induces acetylation of GR; a 
process in which an acetyl group is 
introduced into lysine residues of the 
protein. These acetyl groups are 
subsequently removed by deacetylases, e.g. 
the enzyme histone deacetylase 2 
(HDAC2) that not only targets histones but 
also other proteins. The latter process was 
reported as a crucial mechanism allowing 
GR to inhibit the activity of the pro-
inflammatory NF-κB (3,27). A third 
possible modification is ubiquitinylation, 
an energy-dependent process in which an 
ubiquitin is transferred from an ubiquitin-
activating enzyme (E1) to an ubiquitin-
conjugating enzyme (E2) and finally to the 
target protein by an E3 ligase enzyme (28). 
 Different PTMs can also influence 
each other. For example, specific 
phosphorylation events trigger 
polyubiquitinylation and subsequent 
degradation, which ensures a rapid 
turnover of the receptor and thereby a 
decrease of receptor activity. This outcome 
is not universal and cannot be extrapolated 
to other steroid receptors. Indeed, in 
contrast to GR, ubiquitinylation of the 
estrogen receptor (ER) is even a 
requirement for continued transcriptional 
activity (28). Finally, SUMOylation refers 
to the covalent attachment of SUMO 
(Small Ubiquitin-related MOdifier) 
proteins via enzymes similar to those 
mediating ubiquitinylation. SUMOylation 
sites in the GR are located in the N-
terminal AF-1 and LBD, and the effect of 
this modification is highly dependent on 
the promoter context (29). Recently, this 
type of modification on a lysine in the 
LBD was found to confer a positive effect 
on GR-mediated transcription, in contrast 
to N-terminal domain SUMOylation. 
Hence, inhibitory and stimulatory SUMO 
sites are present in the GR and 
intriguingly, at higher SUMOylation levels 
the stimulatory site becomes dominant 
over the others (30). Appreciably, it 
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becomes extremely difficult to predict the 
behavior of GR when dissecting only a 
subset of PTMs, and rather, it is the 
complete set of modifications that co-
determines in which direction 
transcriptional events are driven. 
 
THE COMPLEXITY OF 
REGULATION BY COFACTORS 
 
 In 1995 the first nuclear receptor 
coactivators were cloned (31,32), soon 
after followed by corepressors (33,34). 
Nowadays, it has become clear that the 
delineation coactivator-corepressor is not 
as sharp as originally assumed, and that 
coactivators can turn into corepressors, 
depending on the cellular context and 
identity of the genes being targeted 
(35,36). Coactivators/corepressors, or 
taken together as so-called coregulators, 
bridge GR with the transcription initiation 
complex and influence the activity of RNA 
polymerase II. The conformational change 
elicited by ligand binding results, next to a 
dissociation of heat shock proteins and 
nuclear translocation, in the formation of 
various interaction surfaces for multiple 
regulatory proteins, the so-called 
coregulators (7,37,38).  
 At the molecular level, the LBD of 
GR consists of α-helices which form a 
hydrophobic cavity. AF2, a helix at the C-
terminus of the LBD, is essential for 
ligand-dependent transcriptional activation. 
This activation helix takes different 
positions depending on the presence or 
absence of ligands. Binding of an agonist, 
which is an activating ligand, leads to 
adoption of a so-called 'charge clamp’ 
conformation. This configuration allows 
for the recruitment of coregulators, mainly 
coactivators, which contain the LXXLL 
consensus sequence. The leucine residues 
of this consensus sequence interact with 
the hydrophobic cavity formed by the LBD 
of GR. Many coactivators contain multiple 
LXXLL motifs, which may be used in a 
nuclear receptor-specific manner, thereby 
allowing a modulation of the efficiency of 
the coactivator function. Corepressors 
interact with unbound or antagonist (a 
suppressing ligand)-bound nuclear 
receptors via the longer sequence LXX I/H 
IXXX I/L, also called nuclear receptor 
corepressor (CoRNR)-box, that binds to 
the same hydrophobic cavity as the 
LXXLL motifs. However, this binding 
mode is not possible when the activation 
helix adopts a 'charge clamp' configuration 
in response to agonist binding. In 
conclusion, binding of an agonist 
diminishes the affinity of the receptor for 
CoRNR-box-containing corepressors and 
enhances it for LXXLL-containing 
coactivators. Some corepressors however 
can also be recruited in a ligand-dependent 
manner by the presence of LXXLL motifs, 
and can thus compete with coactivators. 
An example hereof is the ligand-dependent 
corepressor (LCoR) (34).  
 It is not a single coregulator that 
does the job in initiating and perpetuating 
gene expression or vice versa. It is neither 
the sequential activity of one coregulator at 
a time, but rather a dynamic complex of 
coregulators that collaborate, and of which 
the composition can vary substantially. For 
example, coactivator complexes typically 
consist not only of adaptor proteins (e.g. 
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p160 family members) but also of various 
histone-modifying proteins (see next 
chapter), of which the role is to relax or 
condense the chromatin. Coregulator 
complex composition associated with GR, 
as well as the activity of various 
coregulators in the complex depends on the 
tissue type, the identity of the GR-
activating ligand and the specific target 
gene promoter structure (see above). Not 
only GR as a transcription factor is subject 
to post-translational modifications, 
influencing its activity and stability, but 
also the coregulators themselves, down to 
the level of the basal transcription factors 
and RNA polymerase II (34,37,39). All 
these on/off switches at various levels need 
to be integrated and translated to a logic 
transcriptional outcome, of which the 
directionality (gene active or inactive) is 
often hard to predict, and the extent or 
duration of activation or repression even 
harder.  
 In addition to the traditional 
ligands, DNA itself can be regarded as a 
sequence-specific allosteric ligand of the 
GR, a concept which was raised a long 
time ago, but for which more and more 
evidence has been gathered in the past 
decade (16,40,41). The GR-responsive 
DNA sequence can affect the configuration 
and therefore the activity of the receptor 
via the recruitment of specific 
coregulators. The GBSs may differ 
between promoters in sequence, number 
and position relative to the transcription 
start site. As a consequence, both the 
characteristics of the binding site and the 
ligand can define the specific assembly and 
function of coregulators via alterations in 
the receptor structure and, subsequently, 
influence the specificity and magnitude of 
the response of the gene in question 
(16,23,25,40,41). 
 
THE COMPLEXITY OF EPIGENETIC 
MECHANISMS AND THE 
CHROMATIN LANDSCAPE 
 
 DNA methylation and histone 
modifications are epigenetic mechanisms 
that ‘tag’ genes, hereby controlling 
genome functionality at different levels. 
The environment can additionally 
modulate this ‘tagging’ process, a 
phenomenon which is believed to 
contribute to the onset of diseases (42). 
The overall function of GR is regulated by 
various factors including chromatin 
structure, epigenetics, genetic variation and 
the temporal pattern of glucocorticoid 
hormone secretion (43). In epigenetics, 
DNA methylation is a modification most 
often associated with chromatin 
condensation, transcription factor binding 
occlusion and gene silencing (5,34). This 
modification was demonstrated at the GR 
promoter in specific brain regions and 
subsequently shown to influence 
expression of the GR gene. The reduction 
of central GR expression coincided with 
resistance to glucocorticoids. Interestingly, 
it has also been shown that deprivation of 
maternal nurturing correlates with an 
increase in DNA methylation of the GR 
promoter in the hippocampus. Even more 
intriguing, this methylation pattern could 
be passed on to further generations (44). 
Another example that nicely illustrates a 
dynamic cross-talk between epigenetic 
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changes and environmental cues or at least 
individual experience, was found in suicide 
victims with a history of child abuse, 
which display elevated GR promoter 
methylation in their post-mortem 
hippocampi (45). 
 It was mentioned above that GR 
does not act on its own but instead, makes 
part of multifactorial regulatory 
complexes. Engel and Yamamoto (46) 
studied how GR and the coregulator Brm, 
an ATPase subunit of the Swi/Snf 
chromatin remodeling complex, would 
affect each other’s activity and occupancy 
on the genome. Hereto, the effect of a Brm 
knockdown was monitored for several GR 
target genes in cells treated or not with 
GCs. It appeared that GR occupancy on 
DNA and its activity were differentially 
changed at specific primary GR target 
genes, both activated and repressed. Their 
results support multiple distinct patterns of 
an interdependence of GR and Brm. So 
studying only these two variables as 
paradigms for a combinatorial regulation 
within regulatory complexes already 
reveals marked functionally distinct 
assemblies (46).  
 To conclude, both genetic (e.g. 
small nuclear polymorphisms) and 
epigenetic variations will contribute to 
glucocorticoid sensitivity and 
responsiveness. How widespread the 
occurrence of these variants among the 
general population is, is as of yet not clear. 
 
THE COMPLEXITY OF PROTEIN-
PROTEIN INTERACTIONS 
BETWEEN THE GLUCOCORTICOID 
RECEPTOR AND OTHER PROTEINS 
 
 Next to interactions with 
coregulators and chromatin-modifying 
enzymes, the GR binds to a wide range of 
other transcription factors, including the 
pro-inflammatory AP-1, NF-κB and Signal 
Transducers and Activators of 
Transcription (STAT) (14,47). These 
protein-protein interactions generally result 
in the suppression of the transcriptional 
activity of the targeted factor, but 
depending on the context they can also 
enhance gene expression. In contrast to the 
binding of GR to classical or negative 
GREs, this mechanism, called 
transrepression, does not involve DNA-
binding of the receptor, but binding to the 
DNA-bound transcription factor (tethering) 
or occasionally removing the transcription 
factor from its binding site (squelching). 
This direct interference, resulting in a 
protein synthesis-independent inhibition of 
cytokine gene expression, is considered the 
primary anti-inflammatory action 
displayed by the GR (48–50). 
Contradictory, in the case of the pro-
inflammatory stimulus IL-1β, 
transactivation of anti-inflammatory genes 
appears to represent the major anti-
inflammatory mechanism used by the GR. 
Examples of such anti-inflammatory 
proteins are DUSP1, which inactivates all 
three major MAPK pathways, and GILZ 
that among other actions represses both 
AP-1 and NF-κB signaling. Consequently, 
it is important to realize that 
glucocorticoids have distinct effects on 
different inflammatory responses, and that 
not all inflammatory genes are repressed 
by these hormones. This differential 
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regulation may allow preserving necessary 
aspects of host defense or feedback 
regulation (50). 
 Transrepression typically takes 
place in both directions, in which the GR-
mediated gene expression is reciprocally 
suppressed by the same transcription factor 
(25). Understanding the molecular basis 
for transrepression is ongoing, as it 
becomes clear that not one mechanism is 
responsible, but rather several mechanisms 
can be applied depending on context-
specific components. One example of such 
a mechanism is the recruitment of the GR-
interacting protein-1 (GRIP-1), which acts 
in this context as a corepressor, when the 
receptor tethers to the DNA-bound AP-1 or 
NF-κB transcription factor. In addition, 
this complex can deploy different modes of 
action and interfere at different steps of the 
transcription cycle to repress inflammatory 
gene expression (51). 
 A special case of an interaction 
between GR and another protein is the 
crosstalk with the transcription factor 
Peroxisome Proliferator-Activated 
Receptor (PPAR) α. This lipid-activated 
nuclear receptor not only tethers to GRE-
bound GR, which results in a gene-specific 
modulation of GR's transcriptional activity 
(Ratman et al., manuscript in preparation), 
but also enhances the GR-mediated 
transrepression of NF-κB-driven gene 
expression. Via these actions, PPARα can 
circumvent GRE-mediated side-effects and 
additively represses pro-inflammatory 
cytokine expression (52,53). 
 
THE COMPLEXITY OF NON-
GENOMIC GC ACTIONS 
 
 Pleiotropicity and diversity in the 
function of glucocorticoids is also reached 
by the so-called non-genomic action 
mechanisms. These mechanisms include 
for example the effect of glucocorticoids 
on the phosphorylation and activation of 
MAP kinases. Depending on the cell type, 
it has been shown that glucocorticoids can 
inhibit cytokine-induced JNK, ERK or p38 
kinases by blocking the phosphorylation 
step that is needed to activate these kinases 
(reviewed in (14)). GR and JNK have 
further been demonstrated to interact 
physically and JNK can also phosphorylate 
hGR at position S226, inhibiting the 
transcriptional activation of GR (reviewed 
in (25)). Other non-genomic mechanisms 
of glucocorticoids include receptor-
independent observations, deemed 
responsible for e.g. the rapid inhibitory 
effects on human neutrophil degranulation 
at the cellular level (54), and activities via 
a membrane-bound GR supporting the 
occurrence of rapid anti-inflammatory 
effects (55–57). In a continued attempt to 
resolve the direct and indirect effects of 
GCs, the focus has recently shifted to the 
mitochondria as a newly emerging area of 
intense GC research. It is suspected that 
mitochondria may also be under GC 
control since GR is present in 
mitochondria, and GREs reside in the 
mitochondrial genome (58,59). It is 
currently under investigation which of the 
two main possible mechanisms of GC 
regulation predominates: either a direct 
action on mitochondrial DNA and 
oxidative phosphorylation genes, or an 
indirect effect through the interaction with 
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nuclear genes (59). How GCs can affect 
the broad spectrum of mitochondrial 
functions is an exciting novel field of 
research and results that follow will 
hopefully increase our understanding of yet 
another complexity in GR’s action 
mechanism. 
 
CAN DISSOCIATED GLUCOCOR-
TICOID RECEPTOR MODULATORS 
DECREASE THE COMPLEXITY IN 
BIOLOGICAL OUTCOME? 
 
 During the late nineties, a number 
of findings resulted in the transactivation 
versus transrepression hypothesis. It 
appeared evident at the time that we would 
be able to avoid particular steroid-induced 
side effects when finding ways to 
selectively trigger the GR-dependent 
transrepression pathway (which inhibits 
pro-inflammatory transcription factors NF-
κB and AP-1, for example) without 
sparking the GRE-driven transactivation 
pathway. Especially the diabetogenic side 
effects that relied on transactivation of key 
pathway regulatory genes involved in the 
gluconeogenesis pathway (e.g. glucose-6-
phosphatase and phosphoenol pyruvate 
carboxykinase), and that thus depend on a 
functional GRE in these target gene 
promoters, would be readily ‘avoidable’. 
Some pieces of evidence in support of this 
hypothesis were as follows. First of all, 
upon treating cells with cycloheximide, a 
protein synthesis inhibitor, it was found 
that the repression fold of TNF-induced 
cytokine expression, e.g. IL-6, by 
glucocorticoids remained unhampered 
(60). This finding indicated that novel 
protein synthesis is not a direct need in the 
GR-mediated mechanism targeting 
cytokines. Secondly, the GRdim mouse 
model, a knock-in transgenic mouse model 
in which the GR dimerization abilities 
were compromised due to a GR A458T 
point mutation in the DBD, demonstrated 
that a hampered dimerization, subsequently 
also affecting DNA binding, was still 
compatible with GR-mediated cytokine 
transrepression mechanisms (61). These 
and other findings along the same lines 
(reviewed in (14)) were the start sign for 
many big pharma to embark on a quest to 
develop improved steroids, i.e. so-called 
dissociated glucocorticoids and, in a 
second wave, mostly non-steroidal 
selective GR modulators which favour 
transrepression over transactivation effects 
in an attempt to ultimately reduce the 
number and severity of GR targeting 
therapy-induced side effects (20,62,63). 
The first steroidal structures abiding to this 
sharply differentiating profile in vitro 
proved to be unsuccessful in vivo (64). 
Moreover, it was also found that the 
GRdim mutant could still allow GR-
mediated transactivation on specific 
promoters (16,65). Hence, the GRdim 
mouse did not appear to be the strict 
transrepression-transactivation differentia-
tion tool as first anticipated and would thus 
still be able to support certain specific GR-
mediated transcriptional activation events. 
So far, the fact remains that it has not been 
easy to strictly dissociate anti-
inflammatory effects from adverse effects 
based on the dissociated steroid paradigm, 
and momentarily the field seems heavily 
divided in believers and non-believers of 
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the transactivation versus transrepression 
hypothesis (50,66,67). 
 Well studied by our own research 
team, the one example of a selective GR 
modulator that has so far lived up to 
expectations is Compound A (CpdA) (68). 
In contrast to other GR modulators, CpdA, 
a derivative of a Namibian desert shrub 
isolate, was not engineered or did not 
emerge as a hit following natural 
compound library screens but rather found 
in a serendipitous manner (69). 
Collaborative work with the team of Louw, 
led to the characterization of CpdA as an 
NF-κB-targeting anti-inflammatory 
compound, via GR (68). Various in vivo 
inflammatory mouse models have 
demonstrated that CpdA’s anti-
inflammatory effects (70–73) can be 
combined with a reduction of the 
diabetogenic and hyperinsulinemic side 
effect profile (74), and also with a 
preservation of bone integrity (75). 
Unfortunately, stability issues of CpdA, 
which can be perfectly kept under tight 
control in a lab environment, resulted in a 
dead-end street for CpdA from a druggable 
perspective. 
 Both non-believers and believers of 
the transactivation vs transrepression 
hypothesis have accepted since a long time 
now that the assumption that all beneficial 
effects could be ascribed to 
transrepression, and all devastating effects 
should be attributed to transactivation, is 
just too simplistic and unnuanced. It is 
even way too naïve and almost an offense 
to nature to try to divide GR’s molecular 
mechanisms in merely these two 
categories, since many more mechanisms 
have been described (49,76). As often, the 
truth will lie in the middle. For cases 
subject to GR resistance and particular 
inflammatory models (e.g. antigen-induced 
arthritis or LPS-induced septic shock) 
(77,78), an enhancement of the 
transactivation properties of GR may even 
be desirable (50,67). More studies are 
necessary to further sculpt and support this 
working hypothesis. For other cases and 
particular inflammatory models, e.g. PMA-
induced skin inflammation (79), a more 
sustained and solid transrepression may be 
a more preferable end goal. In addition, 
trying to achieve tissue-selectivity, such as 
recently has been demonstrated for the 
estrogen receptor (80), is an interesting and 
important concept to kindle and investigate 
more, also for GR. 
 Nevertheless, this research area 
clearly needs more work and a further 
unravelment of the fundamental 
mechanisms of GR will undoubtedly be 
helpful to achieve this laudable goal. 
Strongly dissociating GR modulators fulfill 
an important role herein, since they have 
the power to reveal an even broader 
plethora of differential mechanisms that lie 
within GR’s portfolio.  
 
CONCLUSIONS 
 
 To be able to understand how 
glucocorticoids work, an integrated vision 
that assembles the input of all possible 
regulators is needed. The occurrence of 
steroid resistance is the illustration of a 
consequence of combined complexities 
that are gathered in an applied clinical 
setting. There are so many different steps 
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in the GR pathway that could be altered, 
resulting in an ultimate steroid resistance, 
yet arising from different molecular 
phenomena. For example, if one looks at 
the numerous factors that have been 
described to contribute to glucocorticoid 
resistance, a long list of players -which 
might well be non-exclusive contributors- 
emerges. This list contains, among others, 
altered GR isoform levels, GR post-
translational modifications (PTMs) 
(25,81,82), miRNA’s modifying the GC 
response (9,83) and altered levels of pro- 
and anti-apoptotic proteins (84). 
Mechanisms further downstream of GR are 
also implicated in GC resistance; it has 
been proven that various kinase pathways 
(e.g. ERK, JNK and mTOR) oppose GC-
induced apoptosis, while others (e.g. p38 
and PKA) promote it (85,86). Importantly, 
it has also been shown that although a 
decrease in GR levels can contribute to GC 
resistance (6,70), it is apparently not a 
prerequisite for GC resistance to occur in 
hematological malignancies (84,86). 
Bearing this complexity in mind, it is clear 
that a practical solution for steroid 
resistance is not readily in sight. The same 
conclusion can be drawn for other 
examples of the GR regulation and 
signaling complicatedness, such as the 
numerous side-effects provoked by the 
receptor. 
 It may seem that the more we come 
to know about the (complex) action 
mechanisms of GR, the further away we 
drift from the belief that one day we'll hear 
the pieces of the puzzle fall into place with 
a satisfying click, when it comes to getting 
rid of the side effects and upholding 
therapeutic potential. However, the 
ongoing joint effort of many researchers in 
the field should continue for the sake of the 
many sufferers from diseases for which the 
GR is a most welcome positive target. The 
number of patients in need of affordable 
immunosuppressive agents is increasing, 
and the usage of steroids as one of the 
eldest drugs on the market, is, despite the 
side effects and occurrence of resistance, 
not decreasing but on the contrary, steadily 
rising. 
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